For experiment 2, fifty mice were used: wild-type-vehicle = 7, rtTA-vehicle = 7, Bax-vehicle = 7, bigenic-vehicle = 6, wild-type-Dox = 6, rtTA-Dox = 4, Bax-Dox = 7, bigenic-Dox = 6.
No detectable modifications of pulmonary parenchyma were present in the histology of wild-type, vehicle-, or control siRNA-treated mice (Fig. 3A, a1, a2, a3).
In vehicle-treated SERT+ mice, hypoxia caused enhanced pulmonary vascular remodelling relative to hypoxic wild-type vehicle-treated mice and this was also markedly reduced by MPP.
To detect the effect of HSF1 on folding activity, either the pHA-HSF1 wild type?or its vehicle was co-transfected with the reporter plasmids.
To determine whether the PM-induced increase in PAI-1 contributed to the increased tendency toward thrombosis induced by PM exposure, we treated wild type mice with vehicle or etanercept 3 days before and the day of the administration of intratracheal PM.
A cohort of 13 week old R6/2 mice treated with TP-10 or vehicle, and a corresponding cohort of wild type mice treated with vehicle were sacrificed and brains processed for neuropathological assessments.
A cohort of R6/2 mice treated with TP-10 or saline, and a comparison group of wild type mice treated with vehicle, were sacrificed at 13 weeks of age and brains were processed for analysis of mutant huntingtin-induced neuropathology.
Wild type animals treated with vehicle weighed initially 23.6 ± 1.6 g and gained approximately 2.9 ± 1.9 g over the 4-week period.
In the vehicle treated wild type mice, there was only a slight (∼14%) decline in distance traveled from age 5 weeks to age 13 weeks, whereas in the vehicle treated R6/2 mice, distance traveled declined from the level at 5 weeks to a greater extent at 7 (∼40%) and 13 (∼70%) weeks.
Thus, the absence of differences in mRNA levels, in the INT-747 versus vehicle treated wild type mice, for the proteins identified as novel targets, in those selected samples, further increases the value of our finding.
The number of animals used for each study is indicated in Table 2. Treatments beginning at 4 weeks of age included: R6/2 mice administered TP-10 (1.5 mg/kg once per day) dissolved in saline containing 0.5% DMSO, and 0.5% Emulfor™ (Fluka, New York, NY); R6/2 mice administered vehicle only (1 ml/kg once per day), and wild type mice given TP-10 or vehicle.
